Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: Continued risk of biochemical failure after 5 years

Journal of Urology

Volumn 164, Issue 1, 2000, Pages 101-105

  Amling, Christopher L ^a,b   Blute, Michael L ^a   Bergstralh, Erik J ^a   Seay, Thomas M ^a   Slezak, Jeffrey ^a   Zincke, Horst ^a  

^a MAYO CLINIC   (United States)

^b NAVAL MEDICAL CENTER SAN DIEGO   (United States)

Author keywords

Proportional hazards models; Prostate; Prostate specific antigen; Prostatectomy; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0033935812     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67457-5     Document Type: Article

References (26)

1. Zincke, H., Oesterling, J. E., Blute, M. L. et al: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol, Part 2, 152: 1850, 1994
2. Paulson, D. F., Moul, J. W. and Walther, P. J.: Radical prostatectomy for clinical stage T1-2NOMO prostatic adenocarcinoma: long-term results. J Urol, 144: 1180, 1990
3. Gibbons, R. P., Correa, R. J. Jr., Brannen, G. E. et al: Total prostatectomy for clinically localized prostatic cancer: long-term results. J Urol, 141: 564, 1989
4. Trapasso, J. G., deKernion, J. B., Smith, R. B. et al: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol, 152: 1821, 1994
5. Frazier, H. A., Robertson, J. E., Humphrey, P. A. et al: Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy? J Urol, 149: 516, 1993
6. Stein, A., deKernion, J. B., Smith, R. B. et al: Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J Urol, Part 2, 147: 942, 1992
7. Kattan, M. W., Wheeler, T. M. and Scardino, P. T.: Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol, 17: 1499, 1999
8. Ghavamian, R., Blute, M. L., Bergstralh, E. J. et al: Comparison of clinically nonpalpable prostate-specific antigen-detected versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy. Urology, 54: 105, 1999
9. Pound, C. R., Partin, A. W., Epstein, J. I. et al: Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am, 24: 395, 1997
10. Pound, C. R., Partin, A. W., Eisenberger, M. A. et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 281: 1591, 1999
11. Leibman, B. D., Dillioglugil, O., Wheeler, T. M. et al: Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level. Cancer, 76: 2530, 1995
12. Cheng, W. S., Bergstralh, E. J., Frydenberg, M. et al: Prostate-specific antigen levels after radical prostatectomy and immediate adjuvant hormonal treatment for stage D1 prostate cancer are predictive of early disease outcome. Eur Urol, 25: 189, 1994
13. Blute, M. L., Nativ, O., Zincke, H. et al: Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumor deoxyribonucleic acid ploidy. J Urol, 142: 1262, 1989
14. Dillioglugil, O., Leibman, B. D., Kattan, M. W. et al: Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology, 50: 93, 1997
15. Lerner, S. E., Blute, M. L., Bergstralh, E. J. et al: Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol, 156: 137, 1996
16. SAS Institute Inc., SAS/Stat User's Guide, Version 6, Cary, NC, SAS Institute, Inc., 1991
17. Grambsch, P. M. and Therneau, T. M.: Proportional hazards tests and diagnostics based on weighted residuals. University of Minnesota, Division of Biostatistics, Research Report 93-002, 1993
18. Cox, D. R.: Regression models and life-tables. J Royal Stat Soc, Series B, 34: 187, 1972
19. McBride, C. M., Brown, B. W., Thompson, J. R. et al: Can patients with breast cancer be cured of their disease? A sample of the MD Anderson Hospital experience. Cancer, 51: 938, 1983
20. Yamazaki, H., Oshima, A., Murakami, R. et al: A long-term follow-up study of patients with gastric cancer detected by mass screening. Cancer, 63: 613, 1989
21. Saphner, T., Tormey, D. C. and Gray, R.: Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol, 14: 2738, 1996
22. Fisher, B., Bauer, M., Wickerham, D. L. et al: Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer, 52: 1551, 1983
23. Hanks, G. E., Krall, J. M., Hanlon, A. L. et al: Patterns of Care and RTOG studies in prostate cancer: long-term survival, hazard rate observations and possibilities of cure. Int J Radiat Oncol Biol Phys, 28: 39, 1993
24. McLeod, D. G., Sesterhenn, I. S., Moul, J. W. et al: Serum PSA recurrence in patients with pT2 prostate cancer. J Urol, suppl., 159: 61, abstract 226, 1998
25. Dwyer, A. J., Prewitt, J. M. S., Ecker, J. G. et al: Use of the hazard rate to schedule follow-up exams efficiently. An optimization approach to patient management. Med Decis Making, 3: 229, 1983
26. Lashner, B. A., Silverstein, M. D. and Hanauer, S. B.: Hazard rates for dysplasia and cancer in ulcerative colitis. Results from a surveillance program. Dig Dis Sci, 34: 1536, 1989